Symptomatic Popliteal Artery Aneurysms in Recently SARS-CoV-2-Infected Patients: The Microangiopathic Thrombosis That Undermines Treatment.
COVID-19
endovascular treatment
femoro-popliteal bypass
popliteal artery aneurysm
thrombosis
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
09 Feb 2023
09 Feb 2023
Historique:
received:
20
12
2022
revised:
15
01
2023
accepted:
06
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Arterial and venous thrombosis are complications in SARS-CoV-2-infected patients. The microangiopathic thrombosis in affected patients can compromise results in urgent limb revascularizations. Aim of our study is to report on the incidence of symptoms development in patients affected by popliteal artery aneurysm (PAA) and to analyze the effect of COVID-19 infection on outcomes. Data on patients surgically treated for PAA from the massive widespread of COVID-19 vaccine (March 2021) to March 2022 were prospectively collected. Factors considered for analysis were: presence of symptoms, aneurysm diameter and length, time from symptom onset and hospital referral, ongoing or recently COVID-19 infection. Outcomes measures were: death, amputation, and neurological deficit. Between March 2021 and March 2022, 35 patients were surgically treated for PAA. Among them 15 referred to our hospital for symptomatic PAA and were urgently treated. Urgent treatments included both endovascular procedures and open surgeries. Nine out of 15 symptomatic patients had an ongoing or recently recovered COVID-19 infection. COVID-19 infection was strongly associated to symptoms development in patients affected by PAA and to surgical failure in those patients (OR 40, 95% CI 2.01-794.31, In our series, presence of COVID-19 infection was strongly associated to ischemic symptoms onset and to complications after urgent treatment in symptomatic patients.
Sections du résumé
BACKGROUND
BACKGROUND
Arterial and venous thrombosis are complications in SARS-CoV-2-infected patients. The microangiopathic thrombosis in affected patients can compromise results in urgent limb revascularizations. Aim of our study is to report on the incidence of symptoms development in patients affected by popliteal artery aneurysm (PAA) and to analyze the effect of COVID-19 infection on outcomes.
METHODS
METHODS
Data on patients surgically treated for PAA from the massive widespread of COVID-19 vaccine (March 2021) to March 2022 were prospectively collected. Factors considered for analysis were: presence of symptoms, aneurysm diameter and length, time from symptom onset and hospital referral, ongoing or recently COVID-19 infection. Outcomes measures were: death, amputation, and neurological deficit.
RESULTS
RESULTS
Between March 2021 and March 2022, 35 patients were surgically treated for PAA. Among them 15 referred to our hospital for symptomatic PAA and were urgently treated. Urgent treatments included both endovascular procedures and open surgeries. Nine out of 15 symptomatic patients had an ongoing or recently recovered COVID-19 infection. COVID-19 infection was strongly associated to symptoms development in patients affected by PAA and to surgical failure in those patients (OR 40, 95% CI 2.01-794.31,
CONCLUSION
CONCLUSIONS
In our series, presence of COVID-19 infection was strongly associated to ischemic symptoms onset and to complications after urgent treatment in symptomatic patients.
Identifiants
pubmed: 36832134
pii: diagnostics13040647
doi: 10.3390/diagnostics13040647
pmc: PMC9955742
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Surg Case Rep. 2021 Jun 24;84:106133
pubmed: 34175678
J Vasc Surg. 2003 Mar;37(3):586-93
pubmed: 12618697
Br J Surg. 2020 Oct;107(11):1396-1400
pubmed: 33405234
J Vasc Surg. 2022 Jan;75(1S):109S-120S
pubmed: 34023430
J Vasc Surg Cases Innov Tech. 2021 Jun;7(2):267-270
pubmed: 33681541
JMIR Res Protoc. 2019 Mar 14;8(3):e9972
pubmed: 30869648
Vasc Endovascular Surg. 2021 Jul;55(5):429-433
pubmed: 33427109
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
J Vasc Surg. 2022 Jan;75(1):326-342
pubmed: 34390791
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Front Surg. 2022 Aug 23;9:883935
pubmed: 36081587
Inflammation. 2021 Feb;44(1):13-34
pubmed: 33029758
Eur J Vasc Endovasc Surg. 2022 Jan;63(1):80-89
pubmed: 34686452
Ann Vasc Surg. 2021 Feb;71:103-111
pubmed: 33157249
J Vasc Surg. 2020 Dec;72(6):1864-1872
pubmed: 32360679
Rofo. 2020 Apr;192(4):319-326
pubmed: 31461761
BMC Surg. 2022 Nov 18;22(1):398
pubmed: 36401240
Thromb Res. 2020 Aug;192:122-123
pubmed: 32473495
Eur J Vasc Endovasc Surg. 2020 Feb;59(2):173-218
pubmed: 31899099
Ann Vasc Surg. 2023 Feb;89:232-240
pubmed: 36174918
J Vasc Surg. 2021 Aug;74(2):683-684
pubmed: 34303484
Ann Vasc Surg. 2021 Jul;74:73-79
pubmed: 33549797
Cureus. 2021 Jul 18;13(7):e16456
pubmed: 34466301
J Vasc Surg. 2022 Jan;75(1S):121S-125S.e14
pubmed: 34058308
Ann Vasc Surg. 2020 Feb;63:458.e1-458.e6
pubmed: 31648033
Ann Vasc Surg. 2020 Nov;69:74-79
pubmed: 32763458
Eur J Vasc Endovasc Surg. 2020 Feb;59(2):255-264
pubmed: 31917126
Ann Vasc Surg. 2021 Oct;76:1-9
pubmed: 33836228
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120
pubmed: 32172226